Copenhagen, 2013-02-21 11:21 CET (GLOBE NEWSWIRE) -- Zealand Pharma (NASDAQ OMX Copenhagen: ZEAL) announces that a total of 386,012 new warrants have been issued under the new warrant program for employees, established by the company’s Board of Directors under the authority provided by Section 8.1 of the Articles of Association as announced in Company Announcement no. 4/2013 of 8 February 2013. The issued warrants give right to the subscription of up to nominally DKK 386,012 new shares in Zealand Pharma of a nominal value of DKK 1 each at an exercise price of DKK 87.45.
For further description of the issued warrants and the terms of the warrant program, reference is made to Company Announcement no. 4/2013.
The amendment of Zealand Pharma’s Articles of Association entailed by the issue of new warrants has todaybeen registered with the Danish Commerce Agency. The new Articles of Association are attached to this announcement and are also available on the company’s website; www.zealandpharma.com.
# # #
For further information, please contact:
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication
Tel: +45 5060 3689, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved in Europe (February 2013), and under regulatory review in a large number of other countries globally. In February 2013, the FDA accepted for review the NDA submitted for lixisenatide in the US.
Zealand Pharma has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury. Zealand Pharma focuses its activities in disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high. For further information: www.zealandpharma.com
